Does obesity affect treatment response to secukinumab and its survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry.
Ali KarakaşSemih GulleGerçek CanEdiz DalkılıcServet AkarSuleyman Serdar KocaYavuz PehlivanSoner SenelAbdurrahman TufanMehmet Akif OzturkSema YilmazAyten YaziciAyse CefleTuba Yüce İnelYesim Erezİsmail SariMerih BirlikHaner DireskeneliNurullah AkkocFatos OnenPublished in: Modern rheumatology (2023)
This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.
Keyphrases
- ankylosing spondylitis
- insulin resistance
- rheumatoid arthritis
- disease activity
- metabolic syndrome
- weight loss
- type diabetes
- end stage renal disease
- newly diagnosed
- ejection fraction
- weight gain
- high fat diet induced
- systemic lupus erythematosus
- peritoneal dialysis
- emergency department
- electronic health record
- adipose tissue
- prognostic factors
- free survival